[1]
|
Cowan, A.J., Green, D.J., Kwok, M., et al. (2022) Diagnosis and Management of Multiple Myeloma: A Review. JAMA, 327, 464-477. https://doi.org/10.1001/jama.2022.0003
|
[2]
|
Ali, M.O. and Al Hadidi, S. (2022) High Dose (Condi-tioning) Regimens Used Prior to Autologous Stem Cell Transplantation in Multiple Myeloma. Transplantation and Cel-lular Therapy, 28, 572-580.
https://doi.org/10.1016/j.jtct.2022.06.013
|
[3]
|
Garderet, L., Beohou, E., Caillot, D., et al. (2016) Upfront Autolo-gous Stem Cell Transplantation for Newly Diagnosed Elderly Multiple Myeloma Patients: A Prospective Multicenter Study. Haematologica, 101, 1390-1397.
https://doi.org/10.3324/haematol.2016.150334
|
[4]
|
Srour, S.A., Milton, D.R., Bashir, Q., et al. (2021) Melphalan Dose Intensity for Autologous Stem Cell Transplantation in Multiple Myeloma. Haematologica, 106, 3211-3214. https://doi.org/10.3324/haematol.2021.279179
|
[5]
|
Shaw, P.J., Nath, C.E. and Lazarus, H.M. (2014) Not Too Lit-tle, Not Too Much-Just Right! (Better Ways to Give High Dose Melphalan). Bone Marrow Transplant, 49, 1457-1465. https://doi.org/10.1038/bmt.2014.186
|
[6]
|
Aydin, M., Tang, M.W., Wondergem, M.J., et al. (2022) High-Dose Melphalan in 1 Day versus over 2 Days Followed by Autologous Stem Cell Transplantation as Consolidation Treatment in Patients with Multiple Myeloma. British Journal of Haematology, 196, e67-e70. https://doi.org/10.1111/bjh.17980
|
[7]
|
Aljitawi, O.S., Ganguly, S., Abhyankar, S.H., et al. (2014) Phase IIa Cross-Over Study of Propylene Glycol-Free Melphalan (LGD-353) and Alkeran in Multiple Myeloma Autologous Transplantation. Bone Marrow Transplant, 49, 1042-1045. https://doi.org/10.1038/bmt.2014.120
|
[8]
|
Monahan, K., Kleman, A., Thapa, B., et al. (2020) Propylene Glycol-Free Melphalan versus PG-Melphalan as Conditioning for Autologous Hematopoietic Cell Transplantation for Myeloma. Biology of Blood and Marrow Transplantation, 26, 2229-2236. https://doi.org/10.1016/j.bbmt.2020.08.030
|
[9]
|
Jung, S.H., Lee, J.J., Kim, J.S., et al. (2018) Phase 2 Study of an Intravenous Busulfan and Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (KMM150). Biology of Blood and Marrow Transplantation, 24, 923-929. https://doi.org/10.1016/j.bbmt.2018.01.004
|
[10]
|
Bashir, Q., Thall, P.F., Milton, D.R., et al. (2019) Conditioning with Busulfan plus Melphalan versus Melphalan Alone before Autologous Haemopoietic Cell Transplantation for Multi-ple Myeloma: An Open-Label, Randomised, Phase 3 Trial. The Lancet Haematology, 6, e266-e275. https://doi.org/10.1016/S2352-3026(19)30023-7
|
[11]
|
Gao, F., Lin, M.S., You, J.S., et al. (2021) Long-Term Out-comes of Busulfan plus Melphalan-Based versus Melphalan 200 mg/m2 Conditioning Regimens for Autologous Hema-topoietic Stem Cell Transplantation in Patients with Multiple Myeloma: A Systematic Review and Meta-Analysis. Cancer Cell International, 21, Article No. 601.
https://doi.org/10.1186/s12935-021-02313-z
|
[12]
|
Hagen, P., D’Souza, A., Hari, P., et al. (2020) Busulfan, Mel-phalan, and Bortezomib Compared to Melphalan as a High Dose Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma: Long Term Follow Up of a Novel High Dose Regimen. Leukemia & Lymphoma, 61, 3484-3492.
https://doi.org/10.1080/10428194.2020.1811275
|
[13]
|
Veeraputhiran, M., Jain, T., Deol, A., et al. (2015) BEAM Conditioning Regimen Has Higher Toxicity Compared with High-Dose Melphalan for Salvage Autologous Hematopoi-etic Stem Cell Transplantation in Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 15, 531-535. https://doi.org/10.1016/j.clml.2015.05.008
|
[14]
|
Farag, S., Bacher, U., Jeker, B., et al. (2022) Adding Bendamustine to Melphalan before ASCT Improves CR Rate in Myeloma vs. Melphalan Alone: A Randomized Phase-2 Trial. Bone Marrow Transplant, 57, 990-997.
https://doi.org/10.1038/s41409-022-01681-y
|
[15]
|
Gomez-Arteaga, A., Mark, T.M., Guarneri, D., et al. (2019) High-Dose Bendamustine and Melphalan Conditioning for Autologous Stem Cell Transplantation for Patients with Mul-tiple Myeloma. Bone Marrow Transplant, 54, 2027-2038.
https://doi.org/10.1038/s41409-019-0587-0
|
[16]
|
Roussel, M., Moreau, P., Huynh, A., et al. (2010) Bortezomib and High-Dose Melphalan as Conditioning Regimen before Autologous Stem Cell Transplantation in Patients with de Novo Multiple Myeloma: A Phase 2 Study of the Intergroupe Francophone du Myelome (IFM). Blood, 115, 32-37. https://doi.org/10.1182/blood-2009-06-229658
|
[17]
|
Roussel, M., Lauwers-Cances, V., Macro, M., et al. (2022) Bortezomib and High-Dose Melphalan Conditioning Regimen in Frontline Multiple Myeloma: An IFM Randomized Phase 3 Study. Blood, 139, 2747-2757.
https://doi.org/10.1182/blood.2021014635
|
[18]
|
Biran, N., Rowley, S.D., Vesole, D.H., et al. (2016) A Phase I/II Study of Escalating Doses of Bortezomib in Conjunction with High-Dose Melphalan as a Conditioning Regimen for Salvage Autologous Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma. Biology of Blood and Marrow Transplantation, 22, 2165-2171.
https://doi.org/10.1016/j.bbmt.2016.08.017
|
[19]
|
Dalla Palma, B., Accardi, F., Prezioso, L., et al. (2020) Combining Bortezomib to High Dose Melphalan as Conditioning Regimen Results in the Improvement of the Response Rate in Newly Diagnosed Young Multiple Myeloma Patients. Leukemia & Lymphoma, 61, 1238-1241. https://doi.org/10.1080/10428194.2019.1706735
|
[20]
|
Aypar, E., İzzettin, F.V., Akı, Ş.Z., et al. (2018) Comparison of Conditioning Regimen Toxicities among Autologous Stem Cell Transplantation Eligible Multiple Myeloma Patients: High-Dose Melphalan versus High-Dose Melphalan and Bortezomib. Journal of Oncology Pharmacy Practice, 24, 281-289. https://doi.org/10.1177/1078155217697486
|
[21]
|
Costa, L.J., Landau, H.J., Chhabra, S., et al. (2018) Phase 1/2 Trial of Carfilzomib plus High-Dose Melphalan Preparative Regimen for Salvage Autologous Hematopoietic Cell Transplantation Followed by Maintenance Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma. Bi-ology of Blood and Marrow Transplantation, 24, 1379-1385.
https://doi.org/10.1016/j.bbmt.2018.01.036
|